Successful Treatment of Capture Myopathy and Satellite Transmitter Injury in an Atlantic Yellow-nosed Albatross (Thalassarche chlororhynchos).

An Atlantic yellow-nosed albatross (Thalassarche chlororhynchos) was found on shore 3 days after having been captured at sea by researchers. It presented very lethargic, moderately dehydrated, and in poor body condition. It was mildly hypothermic, with moderate pediculosis, and dark malodorous feces with yellow urates. The bird had a 48-g satellite transmitter attached with a backpack-style chest harness, which caused an ulcerative lesion on the interscapular area. The bird was severely anemic (packed cell volume, 18%), and plasma chemistry results were suggestive of a severe rhabdomyolysis (aspartate transaminase, 3620 U/L; creatine kinase, 100 400 U/L). We hypothesized that capture myopathy occurred because of a combination of capture stress and prolonged physical restraint by researchers, stress associated with repeated attempts by the bird to remove the satellite-transmitter harness, and a lengthy road transport to the rehabilitation center. A treatment protocol, which relied on a combination of aggressive fluid therapy, selenium, vitamins E and B12, and multivitamin supplementation, was administered after the initial physical assessment of the albatross. Isoflurane inhalation anesthesia was used to minimize stress associated with the performed medical procedures (eg, physical examination, removal of the satellite transmitter harness, blood collection, and wound management). Measures were adopted while the bird was hospitalized to reduce stress (eg, quiet and comfortable environment with visual barriers and restricting handling of the patient to experienced staff). Clinical and hematological monitoring was used to assess the patient's condition as the bird gradually recovered while hospitalized. The albatross was successfully released 28 days after the initial presentation, suggesting that the medical protocol employed in this case may be useful for the treatment of capture myopathy in albatrosses and other birds.

SEROLOGICAL SURVEY FOR SELECT INFECTIOUS AGENTS IN WILD MAGELLANIC PENGUINS (SPHENISCUS MAGELLANICUS) IN ARGENTINA, 1994-2008.

Despite being the most numerous penguin species in South America, exposure of the Magellanic Penguin (Spheniscus magellanicus) to pathogens has not yet been thoroughly assessed. We collected serum from 1,058 Magellanic Penguins at 10 breeding colonies along the entire latitudinal range of this species in Argentina. The work spanned 10 breeding seasons over 15 yr (1994-2008). Sera were tested for antibodies to select infectious agents. Antibodies reacting against 16 pathogens were detected (seroprevalence): Aspergillus sp. (15.1%), Chlamydia psittaci (6.5%), Salmonella Pullorum (3.1%), Salmonella Typhimurium (81.3%), Aviadenovirus sp. (18.1%), Duck atadenovirus A (23.6%), Anatid herpesvirus 1 (0.7%), Avian orthoreovirus (3.3%), Avian coronavirus M41 (43.5%), Avian coronavirus C46 (59.8%), Avian coronavirus A99 (37.4%), Avian coronavirus JMK (40.2%), Tremovirus A (0.3%), Avian avulavirus 1 (44.0%), Avian avulavirus 2 (43.8%), and Avian avulavirus 3 (46.6%). No antibodies were detected against nine infectious agents: Gallid alphaherpesvirus 1, Gallid alphaherpesvirus 2, Infectious bursal disease virus, Avastrovirus 2, West Nile virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, and Influenza A virus. While restricted by limitations inherent to serological methods, our results provide baseline knowledge for a key species in the South Atlantic Ocean. This information is valuable for adaptive conservation management in a time of increasing environmental stressors affecting the Patagonian Sea, one of the world's richest pelagic seabird communities.

Empirical Primaquine Treatment of Avian Babesiosis in Seabirds.

Babesia species are tickborne hemoprotozoans. Although experiments have shown that primaquine is highly effective in the treatment of Babesia species infections in mammals, this drug has not been widely used for the treatment of avian babesiosis. Consequently, the treatment of this disease for avian patients has traditionally relied on an empirically established imidocarb treatment. In this study, the authors examined the efficacy of primaquine as a treatment alternative for avian babesiosis (Babesia peircei and Babesia ugwidiensis) in seabirds. Retrospective analysis was performed on the medical records and blood smears of 446 B peircei-positive African penguins (Spheniscus demersus) and 41 B ugwidiensis-positive Cape cormorants (Phalacrocorax capensis) admitted for rehabilitation at the Southern African Foundation for the Conservation of Coastal Birds (SANCCOB, Cape Town, South Africa). Treatment with primaquine (1 mg/kg PO q24h for 10 days) was effective in rapidly and markedly decreasing the proportion of Babesia-positive blood smears in African penguins and Cape cormorants. No regurgitation, loss of appetite, or any other signs after administration of primaquine were observed during the study period. The use of primaquine can be a particularly advantageous treatment alternative for avian babesiosis in circumstances in which it is not possible to determine confidently whether the intraerythrocytic inclusions seen in blood smears correspond to Babesia or Plasmodium or in cases in which there is a coinfection by Babesia and Plasmodium.